Edition:
United Kingdom

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

239.95CHF
17 Aug 2018
Change (% chg)

CHF0.75 (+0.31%)
Prev Close
CHF239.20
Open
CHF240.35
Day's High
CHF241.25
Day's Low
CHF238.70
Volume
1,175,524
Avg. Vol
1,687,606
52-wk High
CHF252.85
52-wk Low
CHF206.35

Latest Key Developments (Source: Significant Developments)

Genentech Says FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Genentech Inc::FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR XOLAIR (OMALIZUMAB) FOR FOOD ALLERGIES.  Full Article

Hoffmann-La Roche Ltd - Health Canada Has Approved Hemlibra (Emicizumab Injection)
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Roche Holding AG ::HOFFMANN-LA ROCHE LIMITED - HEALTH CANADA HAS APPROVED HEMLIBRA (EMICIZUMAB INJECTION) FOR HEMOPHILIA A (CONGENITAL FACTOR VIII DEFICIENCY) PATIENTS.  Full Article

Puretech Health Announces Collaboration With Roche
Friday, 20 Jul 2018 

July 20 (Reuters) - PureTech Health PLC ::PURETECH HEALTH ANNOUNCES COLLABORATION WITH ROCHE TO ADVANCE TECHNOLOGY FOR ORAL ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES.PURETECH HEALTH PLC - PURETECH HEALTH TO RECEIVE UP TO $36 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT, AND EARLY PRECLINICAL MILESTONES.PURETECH HEALTH PLC - PURETECH HEALTH ALSO ELIGIBLE TO POTENTIALLY RECEIVE OVER $1 BILLION IN DEVELOPMENT MILESTONES.  Full Article

Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Celgene Corp ::ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY.CELGENE CORP - PHASE III IMPASSION130 STUDY, WHICH WAS SPONSORED BY ROCHE, MET ITS CO-PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL.CELGENE - OVERALL SURVIVAL IS ENCOURAGING IN PD-L1 POSITIVE POPULATION AT INTERIM ANALYSIS, FOLLOW UP WILL CONTINUE UNTIL NEXT PLANNED ANALYSIS.CELGENE CORP - SAFETY IN TECENTRIQ PLUS ABRAXANE ARM APPEARED CONSISTENT WITH KNOWN SAFETY PROFILES OF INDIVIDUAL MEDICINES.CELGENE CORP - NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH IN TECENTRIQ PLUS ABRAXANE COMBINATION.CELGENE CORP - DATA DEMONSTRATE POTENTIAL ROLE OF ABRAXANE AS PREFERRED CHEMOTHERAPY PARTNER FOR IMMUNOTHERAPY COMBINATIONS.  Full Article

Roche Diagnostics Formally Asks Health Canada To Review Its Harmony Test
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Roche Diagnostics::ROCHE DIAGNOSTICS SAYS HAS FORMALLY ASKED HEALTH CANADA TO REVIEW ITS HARMONY TEST, WHICH IS A BLOOD SCREENING TEST FOR PREGNANT WOMEN.  Full Article

PeptiDream announces expansion of discovery alliance with Genentech
Monday, 25 Jun 2018 

June 25 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today the expansion of its ongoing discovery and optimization collaboration with U.S.- based Genentech .  Full Article

FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
Friday, 8 Jun 2018 

June 8 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED ABBVIE & GENENTECH USA'S VENCLEXTA FOR TREATING PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA.  Full Article

Five Prime Therapeutics Announces Collaboration With Roche
Wednesday, 30 May 2018 

May 30 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES.FIVE PRIME THERAPEUTICS INC - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED..  Full Article

Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis
Monday, 21 May 2018 

May 21 (Reuters) - :GENENTECH'S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS.GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION.  Full Article

FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1
Friday, 18 May 2018 

May 18 (Reuters) - FDA::U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB).U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ.FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS.U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS.U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN.FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1.  Full Article

Swiss stocks - Factors to watch on Aug 17

ZURICH, Aug 17 The Swiss blue-chip SMI was seen opening 0.1 percent firmer at 9,008 points on Friday, according to premarket indications by bank Julius Baer .